Patrick Lam is currently a Distinguished Professor of Chemistry at Baruch S. Blumberg Institute and Adjunct Professor of Drexel University College of Medicine. He is also the president of Lam Drug Discovery Consultant, L.L.C. He retired from a chemistry director position of Bristol-Myers Squibb Co. Patrick joined DuPont in 1984 and moved to BMS in 2001. Patrick has over 30 years of medicinal chemistry and drug discovery experience.

He was the group leader/co-inventor responsible for the discovery of Eliquis®/Apixaban, a transformational Factor Xa anticoagulant drug. Eliquis® is currently the top-selling small-molecule drug in the world, with around $17B annual sales. In 2015, the Eliquis discovery team received the American Chemical Society Heroes of Chemistry Award. In addition he was one of the group leaders of FXIa and he made one of the seminal innovations on the path to the discovery of Milvexian®, currently in PIII clinical studies.

Patrick is internationally known as the co-discoverer of the powerful Chan-Lam Coupling Reaction. This is the copper-promoted coupling reaction for N/O-arylation with arylboronic acids. Chan-Lam Coupling Reaction to form C-Heteoatom bond is complementary to the 2010 Nobel-prize winning Suzuki-Miyaura Coupling Reaction which makes C-C bond.

Patrick is responsible for a total of eight clinical candidates. His expertise is in innovations in structure-based drug design, ADME-T, molecular recognition and nucleic acid therapeutics to deliver biopharma clinical candidates with novel profiles. In recent years, he has been involved in 1. anti-cancer (RAD52 inhibitors based on synthetic lethality princeple); 2. heart failure agents (Hydrogen Sulfide Oxidoreductase inhibitors); 3. antivirals (Yellow Fever inhibitors, HBV capsid and surface antigen inhibitors, HIV-DCSIGN blockers); 4. antithrombotics (FXIa and FXa inhibitors as anticoagulants; P2Y1 and PAR4 antagonists as antiplatelet agents), PCSK9 antisense oligonucleotide (ASO) therapeutics, prodrugs and carbohydrates.

Patrick has authored/co-authored 106 papers/reviews/book chapters and is an inventor on 38 patents/patent applications. He has presented >100 invited seminars worldwide. Patrick has received numerous awards including BMS Ondetti-Cushman Innovation Award for FXa inhibitor discovery in 2003; DuPont-Merck Summit Award for the discovery of cyclic ureas as HIV protease inhibitor capable of displacing the “structured water” in 1993.

Patrick received his Ph.D. from the University of Rochester (Dr. Louis Friedrich) in 1980 and, was a postdoctoral fellow in UCLA (Prof. Mike Jung and the late Prof. Don Cram, 1987 Nobel Laureate in chemistry) in 1980-1984.